Trial Profile
An Open-label Study to Evaluate the Effect of Single Dose GS-6615 on QT, Safety and Tolerability in Subjects With Long QT-3 Syndrome
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Eleclazine (Primary)
- Indications Long QT syndrome
- Focus Pharmacodynamics
- Sponsors Gilead Sciences
- 16 Nov 2014 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 01 Aug 2014 The treatment arms have been changed from 5 to 6 along with changes in endpoints and inclusion/ exclusion criteria, according to ClinicalTrials.gov record.
- 01 Aug 2014 Planned number of patients changed from 25 to 34 as reported by ClinicalTrials.gov.